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Background: The molecular regulators that orchestrate stem cell renewal, proliferation and differentiation along
the mammary epithelial hierarchy remain poorly understood. Here we have performed a large-scale pooled RNAi
screen in primary mouse mammary stem cell (MaSC)-enriched basal cells using 1295 shRNAs against genes principally
involved in transcriptional regulation.
Methods: MaSC-enriched basal cells transduced with lentivirus pools carrying shRNAs were maintained as
non-adherent mammospheres, a system known to support stem and progenitor cells. Integrated shRNAs that
altered culture kinetics were identified by next generation sequencing as relative frequency changes over time.
RNA-seq-based expression profiling coupled with in vitro progenitor and in vivo transplantation assays was used
to confirm a role for candidate genes in mammary stem and/or progenitor cells.
Results: Utilizing a mammosphere-based assay, the screen identified several candidate regulators. Although
some genes had been previously implicated in mammary gland development, the vast majority of genes uncovered
have no known function within the mammary gland. RNA-seq analysis of freshly purified primary mammary epithelial
populations and short-term cultured mammospheres was used to confirm the expression of candidate regulators.
Two genes, Asap1 and Prox1, respectively implicated in breast cancer metastasis and progenitor cell function in
other systems, were selected for further analysis as their roles in the normal mammary gland were unknown. Both
Prox1 and Asap1 were shown to act as negative regulators of progenitor activity in vitro, and Asap1 knock-down
led to a marked increase in repopulating activity in vivo, implying a role in stem cell activity.
Conclusions: This study has revealed a number of novel genes that influence the activity or survival of mammary
stem and/or progenitor cells. Amongst these, we demonstrate that Prox1 and Asap1 behave as negative regulators
of mammary stem/progenitor function. Both of these genes have also been implicated in oncogenesis. Our findings
provide proof of principle for the use of short-term cultured primary MaSC/basal cells in functional RNAi screens.
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The mammary epithelial tree is a bilayered, branched
structure composed of an outer myoepithelial (basal)
layer and an inner luminal layer. The full differentiative
potential of the mammary gland is manifest in response
to pregnancy hormones, when a subset of luminal cells
gives rise to alveolar cells that produce milk, which is
then extruded through the lumena during lactation. The
prospective isolation of mammary stem cells (MaSCs)
that are able to give rise to an entire mammary tree
upon transplantation at the single cell level [1,2] and the
phenotypic identification of several mammary epithelial
progenitor cell (MaPC) populations [3-6] have enhanced
our current understanding of the differentiation hier-
archy. More recently, in vivo genetic tracing experiments
have demonstrated the existence of bipotent MaSCs
[7,8] and long-lived progenitors [7,9,10] that contribute
to morphogenesis in puberty and pregnancy, and ductal
maintenance in the adult gland. However, the molecular
processes underpinning the functions of stem and pro-
genitor cells remain poorly understood.
Genetic manipulation and pathway interference have
been successfully used at the level of single genes to
determine the role of regulators of mammary gland mor-
phogenesis (reviewed in [11]). RNAi screening has pro-
vided novel molecular insights in different cellular
systems but large-scale or genome-wide screens have
not yet been performed in the context of primary mam-
mary epithelial cells. Rather, such screening strategies
have been restricted to mammary epithelial and breast
cancer cell lines, which offer the advantages of being
readily available and amenable to genetic manipulation
[12-15]. In other organs, primary cells have been used in
RNAi screens to study tissue stem and progenitor cell
behavior in more complex and physiological contexts
[16-19]. To explore novel molecular regulators of MaSCs
and MaPCs, we have utilized a targeted shRNA library
to interrogate freshly isolated MaSC-enriched cells
ex vivo. This study supports the use of large shRNA li-
braries to identify novel regulators of mammary epithe-
lial function using a non-adherent mammosphere-based
assay and has revealed several novel regulators of MaSC/
basal cell function.
Results
A pooled shRNA screen for the identification of regulators
of mammary stem/progenitor cells using primary cells
To identify novel regulators of mammary epithelial stem
and progenitor cells, we utilized a GIPZ mouse transcrip-
tion factor gene shRNA library to perform a screen largely
based on proliferation/survival potential using primary
mammary epithelial cells. We selected the non-adherent
mammosphere assay, which is principally a progenitor
assay but is also permissible for the maintenance anddifferentiation of stem cells [20-22] upon short-term
culture. Freshly isolated cells in the CD29hiCD24+ sub-
set (Figure 1A) enriched in transplantable MaSCs,
myoepithelial cells and other basal intermediates
(MaSC/basal) [1] were first tested in the mammosphere
system to study their clonogenic properties ex vivo. Fol-
lowing culture in mammosphere medium, MaSC/basal
cells retained the ability to generate colonies in both 2D
assays on irradiated NIH/3T3 feeder layer and 3D
Matrigel assays designed to detect MaPC activity (data
not shown and Additional file 1: Figure S1A). Import-
antly, upon transplantation, the ability of mammosphere
cells to repopulate a mammary fat pad was maintained
during culture at a frequency of 1 in 298 mammosphere
cells (Additional file 1: Figure S1B and C).
The suitability of the mammosphere system for a large
scale shRNA library screen was next investigated by
RNA-seq analysis of freshly sorted MaSC/basal cells;
luminal MaPCs (CD29loCD24+CD61+; LP); a mature
luminal cell-enriched (CD29loCD24+CD61−; ML) popu-
lation; mammosphere-derived cells generated from
MaSC/basal cells harvested after 7 days in non-adherent
culture; and the Comma Dβ cell line, which comprises
bipotent cells capable of mammary reconstitution [23]
(Figure 1B). Comparative analysis revealed that mammo-
sphere cells had an expression profile intermediary to
basal and luminal cell populations indicating that some
luminal lineage gene expression had been initiated dur-
ing culture (Figure 1B). The propensity of MaSC/basal-
derived mammosphere culture to support commitment
to the luminal lineage was demonstrated by the appear-
ance of colonies with an acinar morphology identical to
those derived from luminal MaPCs in Matrigel cultures
(Additional file 1: Figure S1A and data not shown). Not-
ably, global gene expression in the primary mammary
epithelial subsets was more similar to mammosphere
cells than to the Comma Dβ cell line, suggesting that
primary cell-initiated mammospheres represent a more
physiological screening platform than established cell
lines (Figure 1B). Comparison of RNA-seq expression
profiles with previously reported microarray profiles
(Illumina MouseWG-6 v2.0 BeadChip platform [24]) re-
vealed a strong correlation between the two technolo-
gies, however, RNA-seq demonstrated a greater dynamic
expression range and an increased number of differen-
tially expressed transcripts (Additional file 2: Figure S2).
To identify genes that influenced the proliferation or
survival of freshly sorted MaSC/basal cells in mammo-
sphere culture, we screened a customized mouse lenti-
viral library consisting of 1,295 shRNAmirs mostly
targeting transcription factors and represented in 15
pools (Figure 1C). Two rounds of infection of 2 × 106
cells resulted in a transduction frequency of ~40% (data
not shown). Transduced cells were harvested at 24 h or
Figure 1 Differential RNA-seq expression analysis of sorted subpopulations and mammospheres and pooled shRNA screening strategy.
(A) Flow cytometric profiles of Lin− mammary cell populations showing representative sort gates for CD29hiCD24+ MaSC-enriched basal cells
(MaSC/basal), CD29loCD24+CD61+ luminal progenitor-enriched cells (LP) and CD29loCD24+CD61− mature luminal cell-enriched cells (ML).
(B) Multidimensional scaling plot of expression data generated by RNA-Seq of populations including MaSC/basal (Basal), LP and ML populations, MaSC/
basal-derived mammospheres (Mammosphere) and Comma-Dβ cells (CommaDβ). (C) Schematic outline of the screening strategy. (D) Plot showing
the relative frequency of shRNA-carrying cells at T2 and T14 as determined by next-generation sequencing, including a non-silencing control hairpin
(non-sil). Dashed lines, 1.5-fold change. (E) Numerical summary of shRNA performance in the screen.
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sentation of integrated shRNAs was assessed using PCR
from genomic DNA and next generation sequencing.
Adapter and short index sequences in the PCR primers
permitted multiplexing of samples (Figure 1C). Following
next generation sequencing, shRNA read counts within
each indexed sample were determined and changes in
shRNA frequency over time were identified in pre- and
post-culture samples (Figure 1C, D and Additional file 3:
Table S1). With 0.85% of freshly isolated cells expected to
give rise to primary mammospheres and assuming a 40%
infection rate with a pool of 88 shRNAs, the number of
interrogated mammospheres harboring a particular
shRNA would be expected to be above 77 in each repli-
cate experiment. Of note, three to five biological repli-
cates were prepared for each of the 15 pools yielding a
total of 102 samples.From a total of 1,295 shRNAs analyzed in the screen,
sequence read data was obtained for 1,247 shRNAs
(Figure 1E and Additional file 3: Table S1). Eighty shRNAs
targeting 73 genes significantly altered sphere growth
(FDR < 0.01), with 15 shRNAs conferring a >1.5-fold
growth advantage and a 21 shRNAs showing a >1.5-fold
reduced prevalence (Figure 1D, E and Table 1). Among
deleterious shRNAs were those targeting essential genes
such as the TATA binding protein (Tbp), which is required
for transcription (Table 1). Notably, several known reg-
ulators of mammary gland morphogenesis and/or epi-
thelial proliferation, such as Ovol2 [25] and Id1 [26,27],
were found to be significantly depleted (Figure 1D and
Table 1). Moreover, basally-expressed transcription
factors (Tcf4 and Lef1) that are implicated in mammary
stem cell renewal through the Wnt pathway were
depleted in the functional screen [28]. Although Snai2
Table 1 Table of shRNA clones eliciting frequency changes with a FDR ≤ 0.01
Vendor clone ID Gene logFC logCPM PValue FDR
V2LMM_6871 MYOG −2.5393 9.6584 5.24E-39 4.61E-37
V2LMM_68084 ASAP1 1.2699 13.5019 7.53E-29 6.62E-27
V2LMM_63192 LASS6 −1.5047 12.8189 3.47E-23 3.06E-21
V2LMM_64405 NR0B1 −1.2213 12.6156 3.74E-14 3.29E-12
V2LMM_189334 SOX21 0.7841 14.1110 7.57E-11 6.66E-09
V2LMM_82812 Id1 −0.4067 14.0413 1.58E-10 9.96E-09
V2LMM_73029 Myst1 −0.3976 13.7299 4.37E-10 1.38E-08
V2LMM_62263 TBP −0.9262 6.8162 5.90E-10 2.60E-08
V2LMM_25195 TCEA2 −0.9252 13.0207 6.44E-10 2.69E-08
V2LMM_13506 NKX3-1 −0.9163 13.0783 9.16E-10 2.69E-08
V2LMM_54422 POU1F1 −0.9631 12.8253 1.91E-09 8.39E-08
V2LMM_9553 FOXN1 −1.0459 12.0477 8.86E-09 3.90E-07
V2LMM_259235 FOXC2 0.6794 11.6227 3.67E-08 1.61E-06
V2LMM_53719 TEF −0.7084 12.9529 3.54E-08 2.24E-06
V2LMM_27467 NFE2L1 −0.7027 12.1790 5.10E-08 2.24E-06
V2LMM_937 MNT 0.8370 13.6556 1.60E-07 4.71E-06
V2LMM_20404 MAFG 0.7503 14.4488 4.96E-07 1.09E-05
V2LMM_218286 SOX9 0.5992 14.6443 5.34E-07 1.57E-05
V2LMM_29411 Ezh2 0.3074 13.6843 1.37E-06 2.89E-05
V2LMM_64907 NR1H3 −0.6947 13.0997 3.26E-06 5.74E-05
V2LMM_226932 NOTCH2 −0.7216 12.6071 7.35E-07 6.47E-05
V2LMM_22166 NR1H4 0.6672 14.0499 7.62E-06 1.12E-04
V2LMM_70598 Klf4 −0.2842 13.7153 7.81E-06 1.23E-04
V2LMM_29885 Lmo2 −0.2790 13.3138 1.25E-05 1.57E-04
V2LMM_85045 ZFP449 −0.5770 13.6233 6.17E-06 1.81E-04
V2LMM_27178 TRPS1 −0.7064 12.9042 9.70E-06 2.13E-04
V2LMM_7277 NRARP 0.5023 13.3971 8.02E-06 2.35E-04
V2LMM_71087 LEF1 −0.6382 13.1210 1.87E-05 2.35E-04
V2LMM_37331 OVOL2 −0.4958 12.5577 1.11E-05 2.45E-04
V2LMM_82311 FOXJ1 −0.4883 13.7075 1.41E-05 2.48E-04
V2LMM_30422 Ezh2 0.2667 13.9399 2.73E-05 2.87E-04
V2LMM_86479 HLF 0.6524 13.6835 6.89E-06 3.03E-04
V2LMM_73715 KLF5 −0.6192 12.8163 3.27E-05 3.60E-04
V2LMM_77459 Tcf4 −0.2612 13.7487 4.01E-05 3.61E-04
V2LMM_87315 ANKRD46 0.6747 13.9989 2.27E-05 3.99E-04
V2LMM_249987 ANKRD33 0.5109 14.5653 1.82E-05 4.00E-04
V2LMM_34449 THRB 0.6078 13.7210 4.51E-05 4.32E-04
V2LMM_34394 MRG2 0.6048 13.8720 4.91E-05 4.32E-04
V2LMM_71843 TCF19 −0.5495 13.0225 6.03E-06 5.31E-04
V2LMM_162758 ETS1 0.5252 13.3887 1.45E-05 6.38E-04
V2LMM_103225 Rbbp8 0.2503 13.5222 8.51E-05 6.70E-04
V2LMM_3550 TCF21 0.4517 13.0423 5.97E-05 8.76E-04
V2LMM_61869 TBP −0.6028 13.2274 3.29E-05 9.64E-04
V2LMM_110117 NFATC3 −0.7358 13.2152 4.56E-05 1.34E-03
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Table 1 Table of shRNA clones eliciting frequency changes with a FDR ≤ 0.01 (Continued)
V2LMM_70871 NR1I3 −0.6202 13.2914 9.95E-05 1.36E-03
V2LMM_196851 GATA6 0.6165 13.4939 1.08E-04 1.36E-03
V2LMM_86811 Klf8 −0.2331 14.0270 2.43E-04 1.61E-03
V2LMM_14204 Cbx4 0.2323 14.0165 2.55E-04 1.61E-03
V2LMM_103224 Rbbp8 −0.2249 13.7322 4.06E-04 2.33E-03
V2LMM_2021 MTA3 0.5498 13.3661 2.69E-05 2.37E-03
V2LMM_18790 CLOCK 0.6957 14.2333 1.13E-04 2.49E-03
V2LMM_8902 2410018C20RIK −0.4430 13.8888 1.46E-04 2.57E-03
V2LMM_7952 NR2C1 0.6810 13.8576 1.57E-04 2.76E-03
V2LMM_65378 E2F6 0.4731 12.6660 9.67E-05 2.84E-03
V2LMM_14131 Id3 0.2176 14.1862 6.16E-04 3.23E-03
V2LMM_4616 Cbx4 0.2158 14.2122 6.73E-04 3.26E-03
V2LMM_81587 Klf9 −0.2144 13.9803 7.36E-04 3.31E-03
V2LMM_50581 NR2F2 −0.5745 12.8242 3.14E-04 3.45E-03
V2LMM_71013 HNRPAB −0.5309 13.3310 8.03E-05 3.53E-03
V2LMM_71313 CML3 −0.6586 13.3786 2.59E-04 3.80E-03
V2LMM_46526 PROX1 0.6463 13.6892 3.35E-04 4.21E-03
V2LMM_63443 MAFB −0.4007 13.4709 3.65E-04 4.59E-03
V2LMM_75410 ASB4 −0.3952 13.3161 4.41E-04 4.85E-03
V2LMM_87318 ANKRD46 0.3883 13.7227 5.46E-04 5.11E-03
V2LMM_88650 6430502M16RIK −0.3867 13.5604 5.81E-04 5.11E-03
V2LMM_194038 HOXD8 0.4901 13.8093 1.84E-04 5.39E-03
V2LMM_71230 NR1I3 −0.6275 12.9976 5.00E-04 5.50E-03
V2LMM_79666 PAX8 −0.5296 13.7022 2.58E-04 5.67E-03
V2LMM_64571 GCDH 0.4455 13.2693 2.62E-04 5.76E-03
V2LMM_50262 VDR 0.5204 13.8960 3.27E-04 5.76E-03
V2LMM_66887 LASS4 −0.4153 13.1732 3.99E-04 5.85E-03
V2LMM_71060 GTF2H4 −0.4379 13.3758 3.04E-04 6.58E-03
V2LMM_5760 MYC 0.4271 13.4915 4.15E-04 6.58E-03
V2LMM_6641 PYCARD 0.4248 13.2027 4.49E-04 6.58E-03
V2LMM_29358 TBX20 −0.5067 13.3472 4.76E-04 6.98E-03
V2LMM_212338 PPP1R16B 0.3734 13.6841 8.86E-04 7.09E-03
V2LMM_68781 OTX1 −0.6004 13.2971 8.58E-04 8.39E-03
V2LMM_71737 HOXA5 0.4088 13.7302 7.23E-04 9.08E-03
V2LMM_67978 LASS4 0.3995 12.8183 9.89E-04 9.91E-03
V2LMM_62940 IRX6 −0.3977 13.5485 1.01E-03 9.91E-03
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was not detected in our screen, likely reflecting ineffi-
cient knock-down by the two targeting shRNA hairpins
present in the library. Conversely, we observed enrich-
ment of shRNAs targeting genes previously associated
with mammary hyperplasia in knockout mouse models
including Thrb [29] and Vdr [30] (Figure 1D and Table 1).
Several genes with reported roles in stem cell renewal anddifferentiation in other organ systems were also revealed
by the mammosphere screen, including Prox1 [31,32] and
MafB [33].
To eliminate potential false-positives, RNA-seq was
used to confirm the expression of candidate regulators
in freshly isolated MEC subpopulations. Candidate genes
with average counts per million (CPM) >0.5 were deemed
to be expressed and considered potential regulators. Of
Sheridan et al. BMC Cancer  (2015) 15:221 Page 6 of 13the 73 genes targeted by shRNAs, 68 were expressed in
one or more of the epithelial populations with 63 (93%) also
expressed by mammospheres (Figure 2A). Additionally, a
further four genes (6%) were expressed in mammospheres
but not primary cells, indicating potential upregulation of
these genes during mammosphere culture or selection of a
rare cell type through culture (Figure 2A). Seven (10%)
shRNAs with a FDR < 0.01 targeted genes that were not
expressed at an appreciable level in any population, sug-
gesting shRNA off-target effects (data not shown).
In vitro validation of two candidate regulators, Asap1 and
Prox1
Two candidates, Asap1 (ARF-GAP protein with SH3
domains, ankyrin repeats and plekstrin homology domain)Figure 2 Selection of candidate genes for further analysis. (A) Venn d
RNA-Seq, targeted by shRNAs with FDR < 0.01 in freshly isolated MaSC/b
(Mammosphere) populations. (B) qRT-PCR profiling of two candidate regulato
(C) Immunohistochemistry showing PROX1 and ASAP1 protein expression in
FCM plots showing the relative abundance of MaSC/basal cells transduced wi
cells transduced with control mCherry-expressing retrovirus at Day 2 and Day
shRNA-GFP+: mCherry+ cells for each shRNA between 2 and 7 days of co-cult
Statistical significance was calculated relative to shControl: shProx1, p≤ 0.035;and Prox1 (Prospero homeobox 1) were chosen for further
study. Hairpins against either of these genes were enriched
during the screen, indicating that their knock-down
promoted the proliferation/survival of basal epithelial
cells. Asap1 is a multi-domain member of the ARF-
GAP protein family and has roles in metastasis in
several systems including breast cancer cell lines, in
which it has been implicated in invasion and meta-
static potential [34]. However, a role for Asap1 in
normal developmental processes has not yet been
described. Prox1 is a homeobox transcription factor
that exerts multiple roles in different organs includ-
ing lineage specification [31,35] and maintenance of
lineage identity, but its role in the mammary gland
also remains unknown.iagram summarizing expression of genes, as determined by
asal, LP and ML populations and MaSC/basal-derived mammosphere
rs, Prox1 and Asap1, in primary epithelial subsets (n = 3; mean ± S.E.M).
mammary epithelial cells of 8-week-old virgin mice. (D) Representative
th shControl-GFP, shProx1-GFP or shAsap1-GFP retrovirus and competitor
7 in i3T3 cultures. (E) Histogram showing the change in the ratio of






























































































Figure 3 Prox1 is a negative regulator of mammary epithelial
progenitor cells in vitro. (A) qRT-PCR detection of Prox1 transcript
abundance in MaSC/basal cells following transduction with retroviruses
expressing shControl or shRNAs targeting Prox1. Data are shown as
mean ± S.E.M. Prox1 expression normalized to Ywhaz1 expression
relative to shControl (n = 2). (B) Transduced cells (500) were plated
on an i3T3 feeder layer and cultured for 6 days to allow the formation
of colonies. Left panel: representative images of observed colonies.
Right panel: histogram showing the number of colonies derived
from cells transduced with shControl- and shProx1-retroviruses. Data
are shown as mean ± S.D for three independent experiments. (C)
Haematoxylin and eosin staining and anti-P63 (myoepithelial) and
anti-K8/K18 (luminal) immunohistochemical staining of outgrowths
derived from cells transduced with a control versus shProx1 retrovirus.
Scale bars, 50 μm.
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increased in frequency nearly 2.5-fold (FDR, 7.1 × 10−27)
whereas shProx1-carrying cells increased more than 1.6-
fold (FDR, 4.2 × 10−3; Table 1). Expression profiling
confirmed that Asap1 and Prox1 were expressed in all
mammary epithelial subpopulations but showed differ-
ential expression between the MaSC/basal and luminal
subpopulations (Figure 2B and C). To validate shRNA
representation differences observed in the screen, indi-
vidual shRNAs were first evaluated in a competitive cell
assay for cell growth. Over the course of 14 days in cul-
ture, the relative abundance of sorted MaSC/basal cells
transduced with virus-encoded shRNA-GFP versus a
reference population of MaSC/basal cells transduced
with a virus-encoded mCherry fluorescent protein was
measured by flow cytometry (Figure 2D). Changes in the
ratio of shRNA-GFP+: mCherry+ cells revealed the effect
of shRNAs on cell ‘fitness’ (Figure 2D and E). To avoid
potential silencing of the CMV promoter that drives
shRNA and GFP expression in the pGIPZ lentiviral
vector, shRNAs were re-cloned into the retroviral LMS
vector, which remains active in mammary epithelial cells
throughout culture and is permissive for the mainten-
ance of stem and progenitor cells [36]. Sorted MaSC/
basal cells were plated on an irradiated NIH/3T3 (i3T3)
monolayer to support their growth and then transduced.
Consistent with our screen results, cells carrying shA-
sap1 or shProx1 were enriched during co-culture and
both shRNAs stimulated colony growth at day 7 and 14
after plating (Figure 2C, D and data not shown). The
relative numbers of shRNA-GFP+ cells for shProx1 were
expanded by approximately 4-fold following a short
culture period of 5 days (p = 0.028) (Figure 2D and E),
while shAsap1 conferred a more modest advantage of
1.5-fold (p = 0.011) (Figure 2D and E). As expected, a
non-silencing control shRNA conferred no advantage on
transduced cells (Figure 2D and E).
Prox1 inhibits the clonogenic potential of mammary
epithelial cells
Two shRNAs against Prox1 (shProx1-1 and shProx1-2)
that reduced Prox1 expression to below 40% of wild-type
levels were selected for further clonogenic assays on
i3T3 feeder layers (Figure 3A). Initially, an established
regulator of mammary progenitor activity, Snai2 [37]
was tested in this system using two shRNAs (shSnai2-1
and shSnai2-2) (Additional file 4: Figure S3A and B).
An 80% reduction in clonogenicity was observed with
these hairpins, supporting the efficacy of knockdown
and clonogenic readout in this system (Additional file 4:
Figure S3C). Cells carrying either Prox1 shRNA demon-
strated a ~ two-fold higher clonogenicity than those
carrying a non-silencing control shRNA (Figure 3B).
Transplantation of MaSC/basal cells transduced withshProx1-expressing retroviruses yielded outgrowths
with normal morphology and did not reveal any differ-
ence in repopulating frequency compared to control
cells (Figure 3C and data not shown). These findings
suggest that Prox1 levels are less critical for the activity
of MaSCs than MaPCs, although the effect of reducing
Prox1 expression to even lower levels is yet to be
determined.
Asap1 suppresses mammary stem and progenitor cell
numbers or activity
Two independent shRNAs that reduced Asap1 expres-
sion to approximately 25% of wild-type levels (Figure 4A)
were used to confirm a role for Asap1 in normal primary




















































































Figure 4 (See legend on next page.)
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Figure 4 Asap1 negatively regulates mammary stem and progenitor cells. (A) Quantitative RT-PCR detection of Asap1 transcript abundance
in MaSC/basal cells following transduction with retroviruses expressing shControl or shRNAs targeting shAsap1. Data are shown as mean ± S.E.M.
(n = 3). Prox1 expression is normalized to Ywhaz1 expression relative to shControl. (B) Left panel: transduced cells were plated on an i3T3 feeder
layer and cultured for 6 days to allow the formation of colonies. Right panel: histogram showing the number of colonies derived from shControl- and
shAsap1-transduced cells. Data are shown as mean ± S.D for 3 independent experiments. (C) Representative whole-mount images of GFP+ outgrowths
derived from transplantation of shControl- or shAsap1-retrovirally transduced MaSC/basal cells. Scale bar, 2 mm. (D) Morphological analysis of
outgrowths. Haematoxylin and eosin staining and immunohistochemical staining for P63 and K8/K18 of outgrowths following transplantation.
Scale bars, 50 μm. (E) Table of limiting dilution analysis of transplantation frequencies of MaSC/basal cells transduced with shControl or shAsap1
retroviruses. The number of transplants and resulting outgrowths is shown as well as the extent of fat pad filling by individual outgrowths.
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resulted in higher progenitor numbers compared to
control cells in 2D clonogenic assays (Figure 4B), con-
firming a role for Asap1 in progenitor cells. Transplant-
ation of shAsap1-transduced cells into clear fat pads
revealed a greater than 3-fold higher repopulation
frequency compared to shControl virus-infected cells
(Figure 4C). Branched GFP+ outgrowths were morpho-
logically similar to those transduced with shControl
retrovirus and exhibited a similar degree of fat-pad
filling (Figure 4C). The typical architecture of these out-
growths was confirmed by immunohistochemical stain-
ing, with an outer layer of myoepithelial cells expressing
p63 and SMA, and a luminal cell layer expressing Cyto-
keratin 8/18 and E-Cadherin (Figure 4D and data not
shown). Moreover, outgrowths derived from Asap1
knock-down cells were capable of full differentiation to
milk-producing alveoli when recipients were subject to
pregnancy (data not shown).Discussion
In this study, we have developed a protocol to identify
novel regulators of mammary stem/progenitor cells
using freshly isolated MaSC-enriched cells for a func-
tional RNAi screen based on pooled shRNA libraries.
Based on three independent biological screens, we iden-
tified shRNAs targeting 73 genes as potential modulators
of stem/progenitor cell behavior with more than half of
those targeting novel genes that have not been previ-
ously implicated in mammary gland development. Al-
though the changes were modest, they were highly
reproducible. Notably, the strategy also identified a num-
ber of known regulators of stem and progenitor cells,
thereby validating the screening strategy. The mammo-
sphere assay primarily reads out progenitor activity,
given that the transplantation frequency of mammo-
sphere cultures is approx. 1 in 300 (read-out for stem
cells) whereas the colony-forming potential of these cells
is around 1 in 20 (read-out for stem/progenitor cells).
The system established here should be immediately ap-
plicable to future sgRNA/CRISPR libraries using pooled
screens [38].Potential limitations associated with this and other
shRNA-based functional screens, include poor coverage
of genes by multiple shRNAs (in this case a mean
shRNA per gene of 2; mode, 1), and incomplete knock-
down of gene expression. The observed modest fold
changes in part reflect the use of primary cells in a
short-term mammosphere assay, which is necessary to
obviate any changes associated with prolonged culture
of epithelial cells, resulting in smaller amounts of mater-
ial post-culture relative to that obtained from the use of
established cell lines. It is noteworthy that the fold-
changes observed here are comparable to those observed
in another in vitro shRNA screen at early time-points
[17].
Further exploration of two genes with verified expres-
sion in the mammary gland, Asap1 and Prox1, revealed
roles in regulating mammary basal progenitor activity.
Retrovirus-mediated knockdown of either gene aug-
mented progenitor cell numbers in colony forming as-
says in vitro. Moreover, knockdown of Asap1 expression
led to a significant increase in the repopulating fre-
quency, suggesting that Asap1 either negatively regulates
MaSC numbers or their activity. Conversely, knockdown
of Prox1 did not affect mammary repopulating potential,
either suggesting that Prox1 does not compromise MaSC
function or that complete knock-down of this gene is re-
quired for an overt phenotype. In other organs, there is
evidence that Prox1 regulates stem and/or progenitor
cell activity in a context-dependent fashion (reviewed in
[39]). Interestingly, both genes have been postulated to
contribute to oncogenesis when overexpressed. ASAP1
has been shown to be necessary for the in vitro invasive
potential and in vivo metastatic potential of specific
breast cancer cell lines including MDA-MB-231 cells
(Onodera et al., 2005), while increased Prox1 expression
promotes the transition of intestinal adenomas to high-
grade dysplasia or carcinoma in situ [40]. Additional ex-
periments using inducible gene knock-out strategies or
CRISPR/Cas9 technology to further reduce or ablate
ASAP1 or PROX1 protein levels will be required to clar-
ify the specific effects of these genes on distinct mam-
mary cell populations during normal development and
to elucidate their roles in breast oncogenesis.
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Mammary cell preparation and cell culture
The preparation of mammary epithelial cell suspensions
from 8–10 week-old FVB/N female mice and flow cyto-
metric purification has been described [1]. Unless other-
wise stated, all chemicals and media components were
purchased from Life Technologies (Carlsbad, CA, USA)
or Sigma (St Louis, MO, USA). For mammosphere cul-
ture, cells were plated in ultra-low adherence plates
(Corning) in mammosphere medium (DMEM/F12 +
Glutamax, 1% penicillin/streptomycin, 10 ng/ml EGF,
10 ng bFGF, 5 μg/ml insulin, 0.5 μg/ml hydrocortisone,
B27 supplement) at 100,000 cells/ml and maintained as
suspension cultures. Medium was exchanged every 3–4
days and spheres were passaged using trypsin-EDTA and
gentle trituration every 7 days before replating at a dens-
ity of not greater than 50,000 cells/ml. For irradiated
NIH/3T3 (i3T3) co-culture, cells were counted manually
and plated in tissue culture plates with i3T3 fibroblasts
(5,000 Rads) in mammary growth medium (DMEM/F12
with glutamax, 1% penicillin/streptomycin, 10 ng/ml
EGF, 5 μg/ml insulin, 0.5 μg/ml hydrocortisone, 20 ng/
ml cholera toxin) with 5% FCS. After overnight incuba-
tion at 37°C in 5% O2/5% CO2, the cultures were chan-
ged to the same medium containing 1% FCS and
incubated for a further 5 days. Colonies were harvested
with trypsin/EDTA for sorting or stained with Giemsa
for imaging and colony enumeration. For 3D colony as-
says, transduced cells were mixed with Matrigel (BD
Biosciences, San Jose, CA) and cultured as described
[1,11]. Cultures were imaged before fixation with 4%
paraformaldehyde and embedded in paraffin. CommaDβ
cells were maintained as previously described [23].
Transplantation and mammary gland outgrowth analysis
GFP-expressing transduced cells sorted by flow cytometry
were manually counted and transplanted at limiting dilu-
tion as described [1], in the presence of 25% growth
factor-reduced Matrigel. GFP+ outgrowths were visualized
using a dissecting microscope (Leica Microsystems Gmbh,
Wetzlar, Germany) and histology performed as described
[3]. Mammary fat pad filling was quantitated comparing
total fat pad area and outgrowth area using Image J soft-
ware. All animal experiments conformed to regulatory
standards and were approved by the Walter and Eliza Hall
Institute (WEHI) Animal Ethics Committee.
Lentivirus production and transduction
A library of GIPZ plasmids expressing shRNAs was
expanded individually in bacteria, then clones were
pooled and plasmids purified yielding 15 pools of 90
shRNAs (Open Biosystems Transcription Factors Gene
Family Library cat#RMM4950) and one pool of 63
shRNAs (Open Biosystems, custom order WEHI_73597).Lentivirus production was initiated by calcium phosphate
transfection of 293T cells with pGIPZ shRNA-containing
vectors and pMD2.G and psPAX2 (Addgene plasmids
12259 and 12260). Viral supernatants were collected at 26
and 44 hr post-transfection and concentrated via ultra-
centrifugation as per manufacturer’s protocol. Pellets were
resuspended in mammary growth medium with 5% FCS,
centrifuged at maximum speed for 5 minutes at room
temperature to remove most serum proteins. Supernatant
containing 100× concentrated virus stored at −80°C. The
titre of each frozen virus stock was assessed biologically.
Briefly, the day prior to transduction, 50,000 293T cells
were seeded into 12-well plates in 293T medium (DMEM
with 10% FCS and 1% penicillin/streptomycin). On the
day of transduction, cells in three wells were counted to
determine the number of cells present at transduction.
Dilutions of virus made in 293T medium containing
5 μg/ml polybrene were used to replace the medium on
remaining wells so that a series of wells were exposed to
decreasing quantities of virus. Following transduction
for 16–24 hr, the medium was changed and 48 hr later,
cells were analyzed for GFP expression by flow cytome-
try. The number of cells at transduction and the amount
of virus added to a well, where the percentage of GFP+
cells was between 1 and 20%, was used to calculate the
transducing units (TU) per ml using the following for-
mula: [Number of cells at transduction × (% GFP+ cells/
100)]/volume of virus (ml). Typical TU of 1 × 108/ml
were achieved. For mammosphere transduction, 2 × 106
purified cells were plated in mammosphere medium
containing 5 μg/ml polybrene and transduced at 0 and
16 hr with 4 × 106 TU. Medium was exchanged after
24 hr and a sample of the culture was taken for analysis
of baseline shRNA frequency (time-point T2). Follow-
ing 14 days in culture, the remaining cells were har-
vested (T14).
Retrovirus cloning, production and transduction
The LMS vector into which the non-silencing, and tar-
geting shRNAs were cloned has been described [41] and
the LMS-shControl, containing a non-specific shRNA
sequence, was obtained from Open Biosystems. Other
shRNA templates were designed as described and PCR
amplified from DNA oligonucleotides using the forward
primer 5’-CAGAAGGCTCGAGAAGGTATATTGCTGT
TGACAGTGAGCG-3’ and the reverse primer 5’-CTA
AAGTAGCCCCTTGAATTCCGAGGCAGTAGGCA-3’
[42]. Alternatively, shRNAs were purchased from Open-
Biosystems as pGIPZ clones. In both cases, 137 bp shRNA
products were isolated using EcoRI and XhoI digestion
and subcloned into the LMS vector. Mature anti-sense
sequences were as follows: shAsap1-1 (Open Biosystems
clone V3LMM_492766), 5’-TTCGTCGTCATTATCTG
CCTGG-3’; shAsap1-2, 5’-ATATTATATAAGTCAGCA
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506363), 5’-TTCTCTGTAACTTTCTCGG-3’; shProx1-
2 (Open Biosystems clone V3LMM_506365), 5’-TTC
ACTCCAATGTCAACCC-3’; shSnai2-1 described pre-
viously [43]; shSnai2-2 5’-CGCAGACCCACTCTGAT
GTAA-3’. For production of retroviruses, Phoenix cells
(10 cm plates) were transfected with 5 μg of vector
using calcium phosphate precipitation and the virus
supernatant was collected and filtered through a
0.45 μm filter at 48 and 72 hr. For transduction, cells on
feeder layers in 6 well-plates were spin infected
(2,500 rpm, 32°C, 1 hr) with 2 ml of viral supernatant
per well containing 5 μg/ml polybrene. Two to four days
after transduction, transduced GFP+ or mCherry+ cells
were purified by flow cytometry.
Immunohistochemistry
Paraffin-embedded sections (5 μm) were subjected to
antigen retrieval using either 10 mM citrate buffer pH6
or Tris-EDTA buffer pH9, then blocked before staining
with primary antibodies overnight at 4°C and incubation
with a biotinylated secondary antibody at RT for 30 min.
The streptavidin-based peroxidase detection system (ABC
reagent, Vector Laboratories, Burlingame, CA) was used
with 3,3-diaminobenzidine as substrate (DAKO, Glostrup,
Denmark). In all cases, an isotype- matched control IgG
was used as a negative control.
Antibodies
For flow cytometry, antibodies against mouse antigens
were purchased from Biolegend (San Diego, CA) or BD
Biosciences (Franklin Lakes, NJ) unless otherwise specified
and included CD24-PE (M1/69), CD31-B (MEC13.3),
TER-119-B (TER-119), CD45-B (30-F11), CD29-FITC
(HMB1-1), CD61-APC and streptavidin-APC-Cy7. For im-
munohistochemistry, the following antibodies were used:
anti-SMA (1A4; Sigma), anti-p63 (4A4), K8/18 (Troma-1;
Developmental Studies Hybridoma Bank, Iowa City),
anti-Keratin 5 (Covance, Emeryville, CA), anti-Keratin
14 (LL002; Novocastra, UK), anti-E-cadherin, anti-ASAP1
(Rockland Immunochemicals Inc., Limerick, PA), anti-
PROX1 (ab37128; Abcam, Cambridge, UK), anti-SNAI2
(#9585 Cell Signaling Technology, Massachussetts, USA).
Secondary antibodies included biotin-conjugated goat
anti-rabbit IgG, rabbit anti-rat IgG and goat anti-mouse
IgG (Vector Laboratories, Burlingame, CA).
shRNA amplicon sequencing and analysis
Genomic DNA was extracted using the DNeasy Blood
kit (Qiagen) from samples taken at T0 and T2 time-
points and shRNA sequences were isolated from 200–
800 μg gDNA (routinely 400 μg) using the PCR protocol
outlined below. Primers were common to all shRNAs.
The Forward primer, 5’-CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTTAGTGAAGCCACAGATGT
A-3’ anneals in the loop region and incorporates the P7
Illumina adapter sequence. The Reverse primer (5’-AAT
GATACGGCGACCACCGAGATCTACACTCTTTCCC
TACACGACGCTCTTCCGATCTXXXXXGTAGCCCC
TTGAATTCCGAG-3’) anneals in a region common to
all shRNAs and incorporates a variable 5 bp index to
enable multiplexing of samples, the P5 Illumina adapter
sequence and the sequencing primer site. Following one
round of PCR with an annealing temperature of 52°C
and a further 30 to 32 cycles with an annealing
temperature of 55°C, indexed, half shRNA products
(168 bp) were pooled and sequenced on an Illumina
GAIIx or HiSeq2000. Processing of the raw sequence
reads was carried out in R as described previously [38].
Briefly, the number of perfect matches for each index-
hairpin combination was tallied to give counts for the
relevant hairpins in each sample. Downstream statistical
analysis of the summarized counts was performed using
the edgeR software (version 2.6.3) [44]. Outlier samples
determined by visual inspection of multidimensional
scaling plots were removed. An exact test for differences
between the T14 and T2 biological replicate samples in
each pool of shRNA was performed assuming a negative
binomial distribution of the counts [45] and a common
dispersion estimate. Log2-fold-changes, p-values and
false discovery rates for each shRNA were reported.
RNA-seq analysis
Total RNA was extracted and purified from: (1) sorted
luminal or basal populations from the mammary glands
of female virgin 8–10 week-old FVB/N mice (three inde-
pendent samples for population), (2) MaSC/basal cells
cultured for 1 week under mammosphere conditions,
and (3) Comma Dβ cells grown under maintenance con-
ditions [23]. Total RNA (100 ng) was used to generate
sequencing libraries for whole transcriptome analysis
following the Illumina’s TruSeq RNA v2 sample prepar-
ation protocol. Completed libraries were sequenced on
HiSeq 2000 with TruSeq SBS Kit v3- HS reagents (Illu-
mina) as 100 bp single-end reads at the Australian Gen-
ome Research Facility (AGRF), Melbourne. An average
of 62 million 100 bp single-end reads were obtained per
sample. Reads were aligned to the mouse reference gen-
ome (mm10) using the Rsubread package (version
1.14.1) [46] and assigned to genes using the feature-
Counts method [47]. Data were TMM normalized [48]
and transformed into log2 counts per million. Linear
models with observational-level weights [49] were fitted
to obtain average expression values for each gene in each
sample type and moderated t-statistics were used to
assess differential expression between populations [50]
using the limma package (version 3.20.5) [51]. False
discovery rates [52] were used together with log2-fold-
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GEO Series accession number GSE63310.
For comparison of gene expression across platforms,
previously published microarray data (GSE19446) [24]
were compared with RNA-seq profiles. Where multiple
probes were available for a given gene, the probe with the
highest average expression level was taken as representa-
tive. Genes were matched between platforms using gene
symbols and respective log2-fold changes were plotted.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
software (GraphPad, San Diego, CA). Data are shown as
mean ± standard error of the mean (S.E.M.) or standard
deviation (S.D.), where appropriate. Where applicable,
the Student’s t-test was used, with p < 0.05 considered
statistically significant.
Additional files
Additional file 1: Figure S1. MaSC/basal-derived mammosphere
culture is permissive for the retention of progenitor and stem cell activity.
(A) MaSC/basal cells cultured under mammosphere conditions generate
multiple colony types including those with a luminal acinar morphology
in Matrigel (arrowheads) Scale bar, 1 mm. (B) A carmine-alum stained
whole-mounted mammary epithelial tree formed following transplantation
of 500 MaSC/basal-derived mammosphere cells into a mammary fat pad
pre-cleared of endogenous epithelium. (C) Table of limiting dilution analysis
of transplanted mammosphere cells.
Additional file 2: Figure S2. Comparison between RNA-Seq expression
profiles of primary mammary epithelial cell populations with the Illumina
MouseWG-6 v2.0 BeadChip dataset. Plots showing differential expression
of genes in the MaSC/basal versus luminal progenitor (LP) subset, MaSC/
basal versus mature luminal (ML) cell subset and LP versus ML subset, as
determined by microarray [24] and RNA-Seq. Genes differentially expressed
with log2-fold-change > 2 and FDR < 0.001 were enumerated with those
identifiable by both platforms highlighted in blue, RNA-Seq-only in yellow
and microarray-only in red.
Additional file 3: Table S1. Table of shRNA clones included in the screen.
Additional file 4: Figure S3. Snai2 is a positive regulator of mammary
epithelial progenitor cells in vitro. (A) qRT-PCR detection of Snai2 transcript
abundance in MaSC/basal cells following transduction with retroviruses
expressing shControl or shRNAs targeting Snai2. Data are shown as mean ±
S.D. Snai2 expression normalized to Gapdh expression is shown relative to
shControl (n > 3). (B) Western blot analysis of Snai2 protein in MaSC/basal
cells following transduction with retroviruses expressing shControl or shRNAs
targeting Snai2. (C) Transduced cells (500) were plated on an i3T3 feeder
layer and cultured for 6 days to allow the formation of colonies. Left panel:
histogram showing the number of colonies derived from cells transduced
with shControl- and shSnai2-retroviruses. Data are shown as mean ± S.D for
three independent experiments. Right panel: representative images of
observed colonies. Scale bar, 0.5 cm.
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